The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
142 - If we are providing co-pay assistance program through a third-party, do communications informing physicians/HCP of the program have to go through PAAB?
FYI post-approval change/preclearance exemption/what requires review/PAAB scope
1
Posts
1
Posters
348
Views
1
Watching
-
PAAB Code section 1.5 allows a review exemption for formulary announcements such as "now on formulary" not linked to a therapeutic message in any way. Covered uses are deemed to be therapeutic messages. Generally co-pay assistance programs would mention a drug and a therapeutic use and would fall under Code as "institutional" messages with product mention which would require review. The co-pay message could be part of a product ad with claims and would requires a review.
